When it comes to losing fat without extreme exercise, only a few medicines are worth considering. With the innovation in the medical world, physicians are now recommending the Ozempic weight loss ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are "concerned that the current regulations allow some patients to ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...

The new vials – priced at $399 and $549, respectively, for a month's supply – are a lower-cost alternative to the current injector pen formulation ... latter's Wegovy (semaglutide) brand.

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Novo Nordisk also sells semaglutide as Ozempic for diabetes ... obesity and is currently available in the original singe-dose pen-injector format. Mounjaro has already been launched in other ...